

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/006661 A1

(51) International Patent Classification:

A61K 31/4025 (2006.01) A61P 9/10 (2006.01)
A61P 9/00 (2006.01)

(21) International Application Number:

PCT/US2024/035698

(22) International Filing Date:

27 June 2024 (27.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/511,209 30 June 2023 (30.06.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventor: **URVA, Shweta**; c/o ELI LILLY AND COM-
PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(74) Agent: **VORNDRAN-JONES, MaCharri R.** et al.; ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In-
diana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: THERAPEUTIC USES AND DOSES OF LP(A) DISRUPTER COMPOUNDS

FIGURE 3:

Phase 2: Least Squares Mean $\pm$ 1.96 SE Percent Change Relative to Baseline Versus
Week Profiles



LY = compound 1; n = number of participants in the analysis population with baseline and post-baseline value
at the specified time point; SE=standard error

(57) Abstract: Once-daily, oral doses of the Lp(a) disrupter compound (2S)-3-[3-[[bis[[3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl]methyl]amino]methyl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid, or a pharmaceutically acceptable salt thereof, to be used in the treatment of cardiovascular disease, elevated Lp(a) levels, individuals with elevated Lp(a) levels at risk for cardiovascular events and atherosclerotic cardiovascular disease.

[Continued on next page]

Published:

— with international search report (Art. 21(3))